Low-dose immunotherapy does not increase survival when added to chemotherapy for advanced melanoma

2002 ◽  
Vol 3 (4) ◽  
pp. 162-164
Author(s):  
Omar Eton
Keyword(s):  
Low Dose ◽  
Advanced Melanoma

Phase II Trial of Recombinant Alpha-2b-Interferon and Low-Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma

1988 ◽  
Vol 11 (1) ◽  
pp. 55-59 ◽  
Author(s):  
Scott Wadler ◽  
Avi I. Einzig ◽  
Janice P. Dutcher ◽  
Niculae Ciobanu ◽  
Leon Landau ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Trial ◽  
Advanced Melanoma

Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after dacarbazine in advanced melanoma

1997 ◽  
Vol 7 (Supplement 1) ◽  
pp. S119
Author(s):  
G Rasi ◽  
E Terzoli ◽  
F Izzo ◽  
M Ranuzzi ◽  
E Garaci
Keyword(s):  
Interferon Alpha ◽  
Low Dose ◽  
Combined Treatment ◽  
Advanced Melanoma ◽  
Thymosin Alpha 1

Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma

2000 ◽  
Vol 10 (2) ◽  
pp. 189-192
Author(s):  
G. Rasi ◽  
E. Terzoli ◽  
F. Izzo ◽  
P. Pierimarchi ◽  
M. Ranuzzi ◽  
...  
Keyword(s):  
Low Dose ◽  
Combined Treatment ◽  
Advanced Melanoma ◽  
Interferon Α ◽  
Thymosin Α1

scholarly journals Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

2013 ◽  
Vol 11 (1) ◽  
pp. 135 ◽  
Author(s):  
Laura Ridolfi ◽  
Massimiliano Petrini ◽  
Anna Granato ◽  
Giusy Gentilcore ◽  
Ester Simeone ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cell ◽  
Regulatory T Cells ◽  
Low Dose ◽  
Advanced Melanoma ◽  
Dendritic Cell Vaccination ◽  
Melanoma Patients

scholarly journals Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer

1994 ◽  
Vol 5 (2) ◽  
pp. 179-181 ◽  
Author(s):  
L.T. Vlasveld ◽  
S. Horenblas ◽  
A. Hekman ◽  
A.M. Hilton ◽  
A.C. Dubbelman ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Advanced Melanoma ◽  
Recombinant Interleukin 2

Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3093-3093
Author(s):  
Oliver Klein ◽  
Ian D. Davis ◽  
Grant A. McArthur ◽  
Andrew Mark Haydon ◽  
Phillip Parente ◽  
...  
Keyword(s):  
Clinical Trial ◽  
T Cells ◽  
T Cell ◽  
Metastatic Melanoma ◽  
Cell Response ◽  
Low Dose ◽  
Advanced Melanoma ◽  
T Cell Response ◽  
Cd4 T Cell ◽  
Vaccine Antigen

3093^ Background: We have previously demonstrated potent immunogenicity of the NY-ESO-1/ISCOMATRIX vaccine in patients with resected melanoma; however the same vaccine induced only a few vaccine antigen specific immune responses in patients with advanced disease. Therefore, we have enrolled a second cohort of patients with advanced melanoma in the clinical trial LUD2002-013 to investigate whether pre-treatment with the immune-modulator cyclophosphamide could improve the immunogenicity of the NY-ESO-1/ISCOMATRIX vaccine. Methods: LUD2002-013 was an open-label phase II study intended to evaluate the safety and immunogenicity of the NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. The first cohort of patients received vaccine alone; a second cohort with 19 patients was added after evaluation of responses in Cohort 1 and received vaccine in combination with low-dose cyclophosphamide. Patients received 3 injections of NY-ESO-1 ISCOMATRIX preceded, in Cohort 2, by cyclophosphamide at a dose of 300 mg/m2 every four weeks. Assessment of clinical and immunological responses was undertaken at week 11. Results: Fifteen patients of Cohort 2 completed at least one cycle of vaccination. No objective responses were observed with three patients having stable disease for more than three months. The inclusion of cyclophosphamide into the vaccination protocol did not lead to any significant toxicity. Seven of fourteen patients in Cohort 2 developed a vaccine induced NY-ESO-1 specific CD4 T cell response, a significant increase compared to cohort 1 (p=0.019). No differences were observed in the frequency of vaccine induced antibody or CD8 T cell responses. No change in the frequency of peripheral blood regulatory T cells or myeloid derived suppressor cells was detected. Conclusions: The administration of low dose cyclophosphamide has significantly increased the NY-ESO-1 specific CD4 T cell response of the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma. Given the emerging importance of CD4 T cells in tumour regression, the present findings warrant further clinical exploration of combining cyclophosphamide with vaccines and other immune-modulatory agents. Clinical trial information: NCT00518206.

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 3009-3009 ◽  
Author(s):  
Michael B. Atkins ◽  
Toni K. Choueiri ◽  
F. Stephen Hodi ◽  
John A. Thompson ◽  
Wen-Jen Hwu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase 1 ◽  
Advanced Melanoma ◽  
Phase 1 Study

Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma

2016 ◽  
Vol 65 ◽  
pp. 182-184 ◽  
Author(s):  
Michael C. Kirchberger ◽  
Axel Hauschild ◽  
Gerold Schuler ◽  
Lucie Heinzerling
Keyword(s):  
Low Dose ◽  
Advanced Melanoma

scholarly journals Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

2000 ◽  
Vol 82 (4) ◽  
pp. 812-817 ◽  
Author(s):  
T Eisen ◽  
C Boshoff ◽  
I Mak ◽  
F Sapunar ◽  
M M Vaughan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Phase Ii ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Study ◽  
Advanced Melanoma
Sign in / Sign up

Export Citation Format

Share Document